AbbVie and Bristol-Myers Squibb to assess new cancer therapy regimen

AbbVie has announced a new partnership with Bristol-Myers Squibb that will evaluate the potential benefits of a new combination cancer regimen.

The companies have committed to a clinical trial collaboration assessing the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo as a treatment for c-Met overexpressing non-small cell lung cancer (NSCLC).

A phase Ib study is already underway exploring the tolerability and potential efficacy of this combination in patients with this form of cancer who have failed to respond to one prior line of chemotherapy.

AbbVie has agreed to act as a sponsor for the trial, with specific financial terms of the collaboration remaining undisclosed.

Dr Tom Hudson, vice-president for oncology early discovery and development at AbbVie, said: "Therapeutic advances continue to be achieved every day and we are committed to exploring the potential of our investigational compounds with other approved treatments with the goal to deliver a significant impact to patients."

Opdivo is a multipurpose immunotherapy that has already been approved across a number of cancer types, while ABBV-399 remains limited to investigational use for the time being.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.